Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Loading...
Embargo End Date
ICR Authors
Authors
Tiong, IS
Dillon, R
Ivey, A
Teh, T-C
Nguyen, P
Cummings, N
Taussig, DC
Latif, A-L
Potter, NE
Runglall, M
Russell, NH
Raj, K
Schwarer, AP
Fong, CY
Grigg, AP
Wei, AH
Dillon, R
Ivey, A
Teh, T-C
Nguyen, P
Cummings, N
Taussig, DC
Latif, A-L
Potter, NE
Runglall, M
Russell, NH
Raj, K
Schwarer, AP
Fong, CY
Grigg, AP
Wei, AH
Document Type
Journal Article
Date
2020-05-26
Date Accepted
2020-04-14
Abstract
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD.
Citation
British journal of haematology, 2021, 192 (6), pp. 1026 - 1030
Source Title
Publisher
WILEY
ISSN
0007-1048
eISSN
1365-2141
Collections
Research Team
Acute Leukaemia